---
schema_version: "secwatch.filing_event.v1"
accession: "0000886163-26-000050"
form_type: "8-K"
ticker: "LGND"
cik: "0000886163"
company_name: "LIGAND PHARMACEUTICALS INC"
filed_at: "2026-09-22T11:08:26+00:00"
generated_at: "2026-09-22T11:10:25.359083+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Ligand buys Santen's Ryjunea royalty rights for $23M upfront

## Summary
- $23M upfront acquires 100% interest in tiered low-double-digit-to-high-teens royalty on Ryjunea EMEA net sales.
- Ryjunea is EU/UK's first approved pharmacologic treatment to slow pediatric myopia; EC approved June 2025, UK MHRA Oct 2025.
- Santen licensed EMEA rights from Sydnexis in 2021; Ligand steps into those payment rights; Sydnexis keeps US and other territories.
- Market: ~14M myopia patients in Europe 2025; 1 in 3 children projected affected by 2050.

## SEC filing metadata
- accession: 0000886163-26-000050
- form_type: 8-K
- ticker: LGND
- cik: 0000886163
- company_name: LIGAND PHARMACEUTICALS INC
- filed_at: 2026-09-22T11:08:26+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/886163/000088616326000050/0000886163-26-000050-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/886163/000088616326000050/lgnd-20260922.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000886163-26-000050
- JSON: https://secwatch.observer/filing/0000886163-26-000050.json
- Plain text: https://secwatch.observer/filing/0000886163-26-000050.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.